Association between TP53 gene codon72 polymorphism and prostate cancer risk: A systematic review and meta-analysis.

ABSTRACT: BACKGROUND:TP53 gene polymorphism could increase risks of several kinds of cancer. But it remained controversial whether TP53 gene codon72 polymorphism was associated with the susceptibility to prostate cancer. Thus, we conducted a meta-analysis that evaluated the association between TP53 gene codon72 polymorphism and prostate cancer risk. METHOD:A comprehensive research was performed from PubMed, Embase, Web of Science and China National Knowledge Infrastructure (CNKI) up to December 31, 2018. A random effect model was used to evaluate the effect of the outcome. The statistical analyses were performed with Review Manager 5.3.0 and Stata 14.0. The sensitivity analysis and publication bias tests were also performed to confirm the reliability of this meta-analysis. RESULTS:22 studies included 3146 cases and 4010 controls were involved in this meta-analysis. Overall, no association was observed between TP53 gene codon72 polymorphism and prostate cancer risk (Arg vs Pro: odds ratio [OR]?=?1.12, 95% confidence interval [CI]?=?0.98-1.30; ArgArg vs ProPro: OR?=?1.26, 95% CI?=?0.90-1.75; ProPro vs ArgArg+ ArgPro: OR?=?1.17, 95% CI?=?0.86-1.57; ArgPro+ ProPro vs ArgArg: OR?=?1.21, 95% CI?=?0.97-1.51). Subgroup analyses, based on ethnicity, source of control and Hardy-Weinberg equilibrium (HWE) status, showed consistent results. CONCLUSION:The meta-analysis we performed showed that there was no association of TP53 gene codon72 polymorphism with prostate cancer risk.

SUBMITTER: Han PZ 

PROVIDER: S-EPMC6636943 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature